Presented by: Dr. Kirsten Heiss - Scientist Biomarker Discovery, PEPperPRINT GmbH
Date: November 2, 2021
What kind of autoantibody responses can we see in COVID-19? We conducted a small study in which we analyzed sera from both COVID-19 patients and vaccinated individuals to identify and profile cross-reactivity against human autoantigens. In this webinar held on November 11th 2021, Dr. Kirsten Heiss takes us through the study and describes peptide microarrays can be applied for the analysis of antibody cross-reactivity in the context of infection and autoimmunity.
- Analysis of antibody responses before and after SARS-CoV-2 vaccination on the epitope level
- Screening of antibody responses after SARS-CoV-2 infection and immunization
- Identification of significantly increased IgG and IgA autoantibody responses with life-threatening COVID-19 disease progression
- Use of peptide microarrays for the analysis of antibody cross-reactivity in the context of infection and autoimmunity
About the presenter
Dr. Kirsten Heiss received her PhD in infectious diseases from the Ruprecht-Karls-University Heidelberg in 2006 working on the malaria-causing agent Plasmodium. Further Postdoc studies at the Institute of Immunology at University Hospital Hamburg-Eppendorf enabled her to combine infections with immunology. Back in Heidelberg in 2009, working as scientist at the Center for Infectious Diseases at the University Hospital Heidelberg, her research interests focused on vaccine development and the identification of novel targets for intervention strategies against malaria. In 2018, she joined the R&D unit of PEPperPRINT GmbH and is responsible for the discovery of novel antibody-mediated biomarkers in the field of autoimmune und infectious diseases.